Enanta Pharmaceuticals (ENTA) Cash & Current Investments (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Cash & Current Investments data on file, last reported at $163.8 million in Q1 2026.

• Quarterly Cash & Current Investments fell 15.31% year-over-year to $163.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $163.8 million (down 15.31% YoY) and the FY2025 annual result came in at $188.9 million, up 399.1% from the prior year.
• Cash & Current Investments slipped to $163.8 million in Q1 2026, from $185.8 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $386.6 million in Q2 2023 to a low of $37.8 million in Q3 2024.
• A 5-year average of $210.5 million and a median of $214.5 million in 2022 frame the typical range for Cash & Current Investments.
• The widest YoY moves for Cash & Current Investments: up 399.1% in 2025, down 80.52% in 2025.
• Tracing ENTA's Cash & Current Investments over 5 years: stood at $214.5 million in 2022, then soared by 57.2% to $337.2 million in 2023, then sank by 35.73% to $216.7 million in 2024, then slipped by 14.23% to $185.8 million in 2025, then fell by 11.88% to $163.8 million in 2026.
• The last three Cash & Current Investments figures came in at $163.8 million (Q1 2026), $185.8 million (Q4 2025), and $188.9 million (Q3 2025), per Business Quant data.